Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pseudoephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | RGS12 | O14924 | 1/20 | 0.73 |
| ▸ | GLA | P06280 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | PKM | P14618 | 1/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racephedrine SCHEMBL2081241 | 0.92 | ADRA2C (0.71) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 | |
| Racephedrine SCHEMBL8017708 | 0.92 | ADRA2C (0.71) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 | |
| Pseudoephedrine SCHEMBL2081239 | 0.92 | ADRA2C (0.71) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 | |
| Racephedrine SCHEMBL1785211 | 0.90 | ADRA2C (0.69) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 | |
| Racephedrine SCHEMBL3079361 | 0.90 | ADRA2C (0.69) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 | |
| Pseudoephedrine SCHEMBL3079358 | 0.90 | ADRA2C (0.69) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 | |
| Racephedrine SCHEMBL28507177 | 0.88 | CYP2D6 (0.76) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 | |
| Racephedrine SCHEMBL29009026 | 0.86 | CYP2D6 (0.85) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 | |
| Racephedrine SCHEMBL28739755 | 0.86 | ADRA2C (0.92) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 | |
| Racephedrine SCHEMBL12573578 | 0.86 | CYP2D6 (1.00) | ADRA2CCYP2D6CYP2C19ADRA1ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3362071-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Grünenthal GmbH (DE) | 2018-08-22 | — | — | EP | disclosed |
| WO-2017049294-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2011097269-A9 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2012-12-27 | — | — | WO | disclosed |
| EP-2531200-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | Thar Pharmaceuticals, Inc. (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097269-A1 | CRYSTALLIZATION METHOD AND BIOAVAILABILITY | THAR PHARMACEUTICALS, INC. (US) | 2011-08-11 | — | — | WO | disclosed |